A potential treatment for agitation in patients suffering from Alzheimer’s disease is moving closer to market.
New Haven-based BioXcel Therapeutics has announced the start of its Phase 3 program for its drug candidate BXCL501.
The program’s two studies, dubbed Tranquility II and Tranquility III, will evaluate the investigational drug’s safety and effectiveness in adults 65 years and older with Alzheimer’s who are living in assisted living facilities and nursing homes.